Solid Biosciences Inc. (NASDAQ: SLDB) completed a $240 million private placement on March 6 2026, selling 14,973,257 shares of common stock at $5.61 per share and issuing pre‑funded warrants to purchase up to 27,807,482 shares at a pre‑funded price of $5.609 per share with an exercise price of $0.001. The transaction was priced to satisfy Nasdaq’s Minimum Price requirement and was executed in accordance with Nasdaq rules.
The company will deploy the net proceeds to fund ongoing pipeline development, business development activities, working capital, and other general corporate purposes. The infusion extends Solid’s cash runway into the first half of 2027, building on a $236.1 million cash balance reported as of October 31 2025. The capital will accelerate the SGT‑003 Duchenne muscular dystrophy program and support other pipeline assets such as SGT‑212 for Friedreich’s ataxia and SGT‑501 for catecholaminergic polymorphic ventricular tachycardia.
The placement was led by Leerink Partners and Citigroup, with Cantor acting as co‑lead placement agent. Anchored by a mix of existing and new institutional investors—including Perceptive Advisors, Bain Capital Life Sciences, RA Capital Management, Invus, Vestal Point Capital, Janus Henderson Investors, and Deep Track Capital—the offering was oversubscribed, underscoring strong investor confidence in the company’s strategy and pipeline.
Prior to the raise, Solid reported a Q3 2025 earnings per share of –$0.48, missing the estimate of –$0.43, and is expected to report Q4 2025 earnings on March 5 2026. The company’s competitive landscape includes Sarepta Therapeutics’ approved drug ELEVIDYS, positioning Solid to compete for market share in the Duchenne space. The company’s February 2025 equity offering of approximately $200 million further demonstrates its ongoing need for capital to support clinical development.
The private placement’s oversubscription and participation from a broad base of institutional investors signal robust market confidence in Solid’s gene‑therapy platform and its ability to advance key clinical milestones. The financing strengthens the company’s balance sheet, providing the resources necessary to pursue regulatory approvals and maintain momentum in a highly competitive therapeutic area.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.